Description:
Dagrocorat is a new drug that belongs to the class of immunosuppressive drugs. It has been shown to be effective in treating infectious diseases, including HIV and tuberculosis. Dagrocorat binds to the FKBP-12 protein, which is an immunophilin that regulates cellular functions by binding to specific proteins. This binding prevents the activation of proinflammatory cytokines such as IL-1β and TNF-α, which are produced by macrophages. Dagrocorat also inhibits the production of inflammatory mediators such as prostaglandins and leukotrienes, which are involved in allergic reactions. Dagrocorat has been shown to have pharmacokinetic interactions with other drugs such as statins and growth factors, which may increase its efficacy or cause adverse effects.